Neurologic and psychiatric safety profile of TMC278 compared with efavirenz in treatment-naïve, HIV-1-infected patients: pooled analysis from the randomized, double-blind, Phase III ECHO and THRIVE trials at 48 weeks
暂无分享,去创建一个
B. Clotet | A. Antinori | C. Hicks | C. Rica. | M. Fisher | J. Madruga | A. Mills | M. Stevens | S. Vanveggel | G. Herrera | J. Fourie | K. Natal